These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18581132)

  • 1. Planning health care for patients with Graves' orbitopathy.
    Sasim IV; Berendschot TT; van Isterdael C; Mourits MP
    Graefes Arch Clin Exp Ophthalmol; 2008 Sep; 246(9):1315-21. PubMed ID: 18581132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of surgical correction of upper eyelid retraction in Graves' Orbitopathy.
    Pinas D; O B De Keizer R; Wubbels RJ; van den Bosch WA; Paridaens D
    Acta Ophthalmol; 2021 Jun; 99(4):e608-e613. PubMed ID: 32930505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and the treatment modalities of Graves' orbitopathy in a tertiary referral center in Turkey: changes over two decades.
    Ozturk M; Konuk O; Tarlan B; Yalcın MM; Arıbas YK; Toruner FB; Unal M; Ayvaz G
    Int Ophthalmol; 2023 Feb; 43(2):643-653. PubMed ID: 36030455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of biological sex, age and smoking on Graves' orbitopathy - a ten-year tertiary referral center analysis.
    Oeverhaus M; Winkler L; Stähr K; Daser A; Bechrakis N; Stöhr M; Chen Y; Eckstein A
    Front Endocrinol (Lausanne); 2023; 14():1160172. PubMed ID: 37082130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy.
    Rotondo Dottore G; Torregrossa L; Caturegli P; Ionni I; Sframeli A; Sabini E; Menconi F; Piaggi P; Sellari-Franceschini S; Nardi M; Latrofa F; Vitti P; Marcocci C; Basolo F; Marinò M
    JAMA Ophthalmol; 2018 Jun; 136(6):613-619. PubMed ID: 29710102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
    Perros P; Žarković M; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi A; Bournaud C; Brix TH; Covelli D; Ćirić S; Daumerie C; Eckstein A; Fichter N; Führer D; Hegedüs L; Kahaly GJ; Konuk O; Lareida J; Lazarus J; Leo M; Mathiopoulou L; Menconi F; Morris D; Okosieme O; Orgiazzi J; Pitz S; Salvi M; Vardanian-Vartin C; Wiersinga W; Bernard M; Clarke L; Currò N; Dayan C; Dickinson J; Knežević M; Lane C; Marcocci C; Marinò M; Möller L; Nardi M; Neoh C; Pearce S; von Arx G; Törüner FB
    Br J Ophthalmol; 2015 Nov; 99(11):1531-5. PubMed ID: 25953846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience.
    Prummel MF; Bakker A; Wiersinga WM; Baldeschi L; Mourits MP; Kendall-Taylor P; Perros P; Neoh C; Dickinson AJ; Lazarus JH; Lane CM; Heufelder AE; Kahaly GJ; Pitz S; Orgiazzi J; Hullo A; Pinchera A; Marcocci C; Sartini MS; Rocchi R; Nardi M; Krassas GE; Halkias A
    Eur J Endocrinol; 2003 May; 148(5):491-5. PubMed ID: 12720530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).
    Schuh A; Ayvaz G; Baldeschi L; Baretić M; Bechtold D; Boschi A; Brix TH; Burlacu MC; Ciric J; Covelli D; Currò N; Donati S; Eckstein AK; Fichter N; Führer D; Horn M; Jabłońska-Pawlak A; Juri Mandić J; Kahaly GJ; Konuk O; Langbein A; Lanzolla G; Marcocci C; Marinò M; Miśkiewicz P; Beleslin BN; Pérez-Lázaro A; Pérez-López M; Ponto KA; Quinn A; Rudofsky G; Salvi M; Schittkowski MP; Tanda ML; Toruner F; Vaidya B; Hintschich CR
    Br J Ophthalmol; 2024 Jan; 108(2):294-300. PubMed ID: 36627174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
    Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal management of Graves orbitopathy: a multidisciplinary approach.
    Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
    Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center.
    Leo M; Menconi F; Rocchi R; Latrofa F; Sisti E; Profilo MA; Mazzi B; Albano E; Nardi M; Vitti P; Marcocci C; Marinò M
    Thyroid; 2015 Mar; 25(3):347-51. PubMed ID: 25584927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of signal intensity ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of therapy response in Graves' orbitopathy--a pilot study at 1.5 T.
    Kirsch EC; Kaim AH; De Oliveira MG; von Arx G
    Neuroradiology; 2010 Feb; 52(2):91-7. PubMed ID: 19756565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of orbital radiotherapy in moderate-to-severe active graves' orbitopathy including long-lasting disease: a retrospective analysis.
    Choi JH; Lee JK
    Radiat Oncol; 2020 Sep; 15(1):220. PubMed ID: 32958019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the Development of Orbitopathy in Graves Thyroidopathy Patients: The Potential Role of TSI Testing.
    Takakura A; Kirkeby K; Earle K; Silkiss RZ
    Ophthalmic Plast Reconstr Surg; 2015; 31(5):369-72. PubMed ID: 25585304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronal or swinging eyelid decompression for patients with disfiguring proptosis in Graves' orbitopathy? Comparison of results in one center.
    Sasim IV; de Graaf ME; Berendschot TT; Kalmann R; van Isterdael C; Mourits MP
    Ophthalmology; 2005 Jul; 112(7):1310-5. PubMed ID: 15950284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study.
    Perros P; Žarković MP; Panagiotou GC; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi AM; Nardi M; Brix TH; Covelli D; Daumerie C; Eckstein AK; Fichter N; Ćirić S; Hegedüs L; Kahaly GJ; Konuk O; Lareida JJ; Okosieme OE; Leo M; Mathiopoulou L; Clarke L; Menconi F; Morris DS; Orgiazzi J; Pitz S; Salvi M; Muller I; Knežević M; Wiersinga WM; Currò N; Dayan CM; Marcocci C; Marinò M; Möller L; Pearce SH; Törüner F; Bernard M;
    J Endocrinol Invest; 2020 Dec; 43(12):1717-1722. PubMed ID: 32474767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.